Dr. Koenig has been working in the field of neuroscience since 1987. He received his PhD in neurobiology summa cum laude in in 1991 from the University of Heidelberg, Germany. After a post doc with Konrad Beyreuther at the University of Heidelberg, he joined Bayer Pharmaceuticals CNS group in West Haven, CT in 1993. During his time at Bayer, Gerhard held positions of increasing responsibility in CNS drug discovery. In his last position at Bayer, he was responsible for preclinical research for cognition enhancers in general and Alzheimer’s disease approaches including disease modifiers. Gerhard left Bayer in late 2002 to join Fidelity Investments, the sole investor in EnVivo Pharmaceuticals and shortly thereafter transferred to EnVivo as the Chief Scientific Officer. The nicotinic alpha7 receptor agonist program with its lead compound EVP-6124 was one of several initiated under Gerhard’s leadership and is currently in phase IIb testing.